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Abstract
Mechanisms responsible for the course of the rheumatic diseases have not been fully 
explained. Among the available tools that may help in studies of these mechanisms is molec-
ular imaging—especially techniques emphasized by nuclear medicine. In contrast to CT, MRI 
or US examination that show only structural pathologies, radionuclide methods allow imag-
ing of functional changes that occur in the course of the disease and usually are featured by a 
very high specificity. Recent advances in nuclear medicine allowed to develop target-specific 
agents making it possible to reveal molecular level disturbances that take place on the course 
of the ongoing disease. The fundamental radionuclide studies include PET, SPECT, and 
classic scintigraphy. Technological advances (especially hybrid modalities) allow obtaining 
images of much better resolution and allow combining both structural and functional data.
Keywords: PET, SPECT, markers of inflamation, radiotracers cordially
1. Introduction
Mechanisms responsible for the course of the rheumatic diseases have not been fully explained 
till today. Molecular imaging sits among the available tools that may help in studies of these 
mechanisms, particularly techniques emphasized by nuclear medicine.
In contrast to such imaging modalities as CT, US or MRI, that reveal only structural patholo-
gies, radionuclide methods enable imaging of functional changes that occur in the course of 
the disease and more importantly are usually featured by a very high specificity. Radionuclide 
studies also make it possible to determine the changes in the molar concentration of specific 
chemical compounds up to 10−11 or even 10−3–10−4 if an MRI is used. It means that radionuclide 
studies enable the performance of diagnosis of disorders in the molar concentration of the 
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specific chemical compounds that take place in the course of the disease. It is important to 
note that the functional character of disorders should be the basis for the choice of treatment.
Over the last several decades, the introduction of new biological agents has greatly improved 
the effectiveness of treatment. Those agents influence the activity of specific receptor and 
metabolic pathways [1]. Along with the application of new agents, it has become necessary to 
introduce new diagnostic methods, which allow evaluation of the activity of those biological 
processes. Unfortunately, neither clinical examination nor laboratory tests nor conventional 
X-ray does not provide such findings. A clinical evaluation can be highly subjective; labora-
tory tests are frequently non-specific and inconsistent, while conventional X-ray shows struc-
tural changes only at the advanced stage of the disease.
It seems that the introduction of molecular imaging techniques may lift those limitations. The 
fundamental methods of molecular imaging are radionuclide studies. Recent advances in nuclear 
medicine allowed to develop target-specific agents making it possible to reveal molecular level 
disturbances that take place on the course of the ongoing disease [2]. The fundamental radionu-
clide studies include a PET, SPECT, and classic scintigraphy. Moreover, hybrid devices are used 
more frequently in diagnostics these days—these consist of gamma camera and CR/MRI. Thanks 
to hybrid techniques, it is possible to perform CT/MRI combined with scintigraphy (for example 
PET-CT, PET-MRI, and SPECT-CT). It is also important to mention that the combination of those 
techniques allows applying attenuation correction of the absorbed radiation that is being emitted 
by radioisotope, as well as making it possible to determine the exact location of the abnormal 
uptake of the radiopharmaceutical. Finally, the images obtained are of very high quality.
Technological advances allow obtaining images of much better resolution and allow combin-
ing both structural and functional data. Vogel et al. noted in his study that hybrid imaging 
technique 18F-FDG PET-CT, apart from providing the capability of assessing the degree of 
inflammation localized in the tarsus of a rheumatoid arthritis (RA) patient, also allows precise 
localization of the disease activity in particular joints [3]. Neither physical examination nor 
X-ray can provide such relevant data. Furthermore, 18F-FDG PET/CT allows to visualize and 
diagnose metabolically active subcutaneous nodules, activated lymph nodes or other affected 
joints in the course of the disease (such as those of the knee or atlantoaxial joints). This method 
allows better discrimination between juxtaarticular disease and articular processes as well as 
delineation of tendon sheath and bursal inflammation. Furthermore, this method makes it pos-
sible to delineate inflammation of the tendon sheaths and bursae. Miese et al. [4] also assessed 
the high suitability of PET/MRI apparatus in his work about the diagnosis of RA, in which he 
showed increased uptake of 18F-FDG in the corresponding metacarpophalangeal joints that 
were affected by synovitis and tenovaginitis as identified on contrast-enhanced MRI.
MRI is second modern imaging modality that is very useful in the diagnosis of rheumatic 
diseases. This method features a very high resolution and similarly good contrast between 
the soft tissues. Thanks to the new sequences and specific contrast agents, and modern MRI 
allows imaging of vast amounts of pathologies.
Both of these methods provide the information about molecular pathological mechanisms 
that accompany the disease; thus allowing a better understanding of the pathophysiology of 
rheumatic diseases. Moreover, they allow a search of the new forms of molecular treatment 
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that allow for an early and accurate prognosis as well as monitoring of therapy [5]. Beyond 
any doubts, another important feature of these methods is the capability of making the diag-
nosis at the subclinical phase of the disease, thanks to which a proper treatment can be started 
long before irreversible morphological changes occur.
Procedures offered by nuclear medicine meet the number of important expectations associ-
ated with the development of modern medical sciences, such as:
a. The capability of putting a considerably early diagnosis of pathological changes as well 
as the determination of their character, which is crucial to make an appropriate diagnosis 
before irreversible structural changes occur.
b. The ability of accurate determination of the degree of pathological changes.
c. The ability to predict the course of the disease and the subsequent introduction of person-
alized therapy.
d. The reduction of constantly increasing the costs of medical procedures by use of such eval-
uation tools that provide a good assessment of the effectiveness of the applied treatment.
e. The need of the determination of remission of the pathological changes as well as an early 
diagnosis of their relapse.
Taking these facts into account, it is clear that radionuclide studies and MRI have proven to 
be useful in solving all of the clinical issues. Moreover, it is important to note that it meets 
economic and pharmacological criteria for cost-effectiveness.
2. Radiopharmaceuticals
2.1. 18F-FDG
The most commonly used radiopharmaceutical used in PET-CT studies is fluorodeoxyglu-
cose (18F-FDG), which is a structural glucose analog. Areas of increased tracer uptake indi-
cate the intensification of metabolic processes associated with increased glucose demand. 
This feature can be found both in a tumor and inflammatory setting. Increased uptake of 18F-
FDG is associated with increased activity of the GLUT1 and GLUT3 transport mechanisms 
as well as the activity of hexokinase—these phenomena are typical for cells that undergo 
fast proliferation as well as other types of cells such as macrophages, neutrophils and young 
granulation tissue [6–8].
2.2. 11C-choline
Choline is another tracer that features high sensitivity for proliferative processes that occur in 
the course of the disease. This tracer is uptaken by quickly dividing cells where it undergoes 
phosphorylation by choline kinase into phosphorylcholine. Choline is essential for phos-
pholipids synthesis, especially phosphatidylcholine (also known as lecithin) which serves 
as the building block of the cell membranes. Increased uptake of choline depends on the 
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mechanisms responsible for active transport via the cell membrane as well as on congestion-
dependent passive diffusion. It has been found that increased uptake can be seen even in the 
early phase of the inflammation. Once present, its grade of accumulation corresponds with 
both the extent of the contrast-enhanced signal in an MRI study (with Gadovist as a tracer) 
and the accumulation of 18FDG [9].
2.3. 67Ga-citrate
This radiopharmaceutical has been used in both the diagnosis of cancer as well as acute and 
chronic foci of inflammation for several years. Gallium (administered via i.v. infusion) acts as 
an iron analog that binds to transferrin, ferritin, and leukocytes (primarily neutrophils) [10]. 
These molecules accumulate within the foci of inflammation secondary to increased capillary 
permeability. At the time when 67Ga-bound macromolecules reach the inflammatory inter-
stitial space, the isotope undergoes the process of transchelation into lactoferrin, ferritin and 
bacterial siderophores (if present). Moreover, lactoferrin is then being secreted by neutrophils 
that are present in the inflammatory foci caused by the disorders of the connective tissue 
[11]. Recently, 67Ga-citrate is rarely used because of the vast availability of other—frequently 
much better—markers as well as other factors such as the unfavorable energetic profile of 
the emitted radiation, the long-lasting radioactivity of the blood (due to high affinity to the 
white blood cells) and relatively long half-life time. This results in significantly increased 
absorbed radiation dose in comparison to other radioisotopes, not to mention low quality of 
the obtained images. Another disadvantage of 67Ga-citrate is the lack of specificity for inflam-
mation because it accumulates similarly in neoplasms.
2.4. 99mTc and 111In HIG
Both 99m-technetium and 111-indium can be used for labeling of human (polyclonal) immu-
noglobulins (HIG). HIG accumulate in the inflamed tissues because its mechanism of accumu-
lation is related to the increased permeability of the vascular capillaries as well as increased 
blood flow to the inflamed area. This technique features very high sensitivity, not to mention 
that the grade of its accumulation highly corresponds to the severity of the inflammation, 
hence making it a useful prognostic tool. On the other hand, one of the disadvantages of this 
radiopharmaceutical includes lack of specificity [12].
2.5. 99mTc-diphosphonates
Similarly to gallium-67, 99mTc-diphosphonates are non-specific tracers used in the diagnosis 
of the inflammation—its mechanism of uptake relies on the metabolism of the osseous cells—
its degree of uptake depends on the activity of osteoblasts (hence its perfect for imaging of 
the bone turnover). Bone scintigraphy is readily available and cheap method of evaluation 
of bones [13, 14]. As the severity of the inflammation progress, the uptake increases. In the 
setting of inflammation evaluation, the bone scan comes in the form of a triphasic examina-
tion, which consists of vascular, parenchymal, and late (bony) phase (Figure 1). Each phase 
presents a specific aspect of the pathology:
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• Phase I—hyperemia,
• Phase II—increased volume of the vascular bed,
• Phase III—metabolic turnover and remodeling of the osseous tissue as a result of the ongo-
ing pathology (inflammation and destruction of the cartilage).
This method is highly sensitive but features low specificity, which can be improved by hybrid 
SPECT-CT technique if one is available.
It is important to note that the accumulation of described radiopharmaceuticals in tissues 
affected by inflammation is non-specific because these tracers accumulate similarly in neo-
plastic foci. Due to that fact, there is recently ongoing research that aims to develop markers 
specific for inflammation occurring in the course of the rheumatic diseases.
2.6. Labeled leukocytes
Since the inflammation features the migration of leukocytes, there was an idea to use that 
mechanism in the diagnosis and localization of the inflammatory foci. Nuclear medicine has 
Figure 1. Triphasic bone scan after 99mTc-MDP administration in patient with RA shows increased blood flow (A), blood 
pool (B), and increased accumulation of the radiotracer in the bony phase (C) which indicates increased bony turnover 
in the affected left knee.
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come to meet this need and has developed a radionuclide examination that makes it possible 
to label leukocytes of the patient (both in vitro and in vivo depending on the technique). 
In the setting of inflammation, neutrophils and monocytes are being recruited, and due to 
the phenomena of chemotaxis, they accumulate in the foci of inflammation. Thanks to this 
mechanism of accumulation, labeled leukocytes can be used in the diagnosis of RA as well 
as other inflammatory diseases. Labeled leukocytes emphasize two main techniques—in 
vivo and in vitro assay.
• In vitro assay is a technique that involves taking a blood sample, isolating a leukocyte 
suspension, labeling those leukocytes with 99mTc-HM-PAO or 111In-oxine, and intravenous 
administration back to the patient. It is important to note that this procedure does not affect 
chemotaxis.
• In vivo assay, on the other hand, involves intravenous administration of 99mTc-labeled mono-
clonal antibodies against the specific NC-1 antigen that is present on the granulocyte cell 
membrane. In this procedure, the labeling process occurs directly in the blood of the patient. 
Moreland et al. [15] in his work have shown that there is a direct correlation between the 
foci of increased accumulation and the clinical picture in the course of rheumatoid arthritis. 
This examination may also be used as a tool to control anti-inflammatory treatment [15].
2.7. 11C-PK11195
One of the proposals involved the introduction of 11C-PK11195 isoquinoline carboxamide—
this radiopharmaceutical binds to both monocytes and macrophages and serves as periph-
eral benzodiazepine receptor (PBR) antagonist also known as translocator protein (TSPO). 
This peptide is particularly active on the outer surface of the mitochondrial membrane of the 
activated macrophages, polymorphonuclear cells as well as nervous and lymphatic tissue 
[16–18]. It is responsible for the process of steroidogenesis, apoptosis, cell proliferation, and 
immune response. It has also been proved that this radiopharmaceutical is an effective marker 
in neuroinfection, due to the fact that peripheral benzodiazepine receptors can be typically 
found on activated glial cells.
2.8. 99mTc-J001X
Other noteworthy markers are those with the ability to label the macrophages. These kinds 
of cells are particularly active in inflammation based on the rheumatic disorders and play 
a major role in the inflammatory process. It was found that macrophages bind specifically 
to the proteoglycans of the bacteria. Hence a technique of proteoglycans labeling has been 
developed [19, 20].
Recently used tracer is called J001X—which is a poly-(1,3)-d-galactoside isolated from the 
cellular membrane of Klebsiella pneumoniae. This 99mTc labeled-substance allows tracing of the 
mononuclear phagocytes.
The effectiveness of this radiopharmaceutical in the diagnosis of RA-associated lung pathol-
ogy appears to be promising, but until today there is no randomized study that would 
confirm its effectiveness. Lastly, this tracer was also used in imaging of sarcoidosis and 
scleroderma [21].
Newest Updates in Rheumatology14
2.9. 99mTc-RP128
99mTc-RP128 is a peptide tracer used for imaging of leukocytes recruitment used for labeling of 
neutrophils and mononuclear phagocytes. 99mTc-RP128 is a pentapeptide tuftsin analog antag-
onist (TKPPR) that mediates the receptor-specific interaction and subsequently binds to tuft-
sin receptors. Tuftsin is an organic chemical compound consisting of amino acid residues such 
as threonine, lysine, proline, and arginine. It is produced by the spleen and its function is to 
stimulate macrophages and granulocytes to phagocytosis and chemotaxis. Tuftsin is derived 
from proteolytic cleavage of the Fc domain of the heavy chain of IgG. Tuftsin receptor's func-
tion is to mediate the immune functions; hence they represent important molecular targets. 
The mechanism of RP128 imaging is based on the upregulation of tuftsin receptors located in 
activated macrophages. Chaudhuri et al. [22] noted that the affinity of radiotracer is fourfold 
greater than their endogenous ligand. Despite that fact, this radiotracer was described only 
in a few works; thus there is a need for further research that would confirm its utility. Studies 
show that it accumulates in other organs to an only small extent (except kidneys). The grade 
of accumulation in healthy joints was moderate—in contrast to the affected joints, which 
featured a very high uptake. The sensitivity of the scan was 69% for swollen joints, 76% for 
painful joints, and 73% for joints with bone erosions [23].
2.10. 99mTc- and 111In anti-E-selectin
Adhesion is another mechanism used in the diagnosis of the inflammation. Molecules respon-
sible for this phenomena cause leukocytes to bind to the activated endothelial vessels result-
ing in their transendothelial migration. One of such molecules that are used in the diagnosis 
of the inflammation is E-selectin labeled with 99mTc or 111In. E-selectin (CD62E, ELAM1) is a 
transmembrane glycoprotein that is transiently expressed on the luminal surface of activated 
vascular endothelium during a normal inflammatory response. E-selectin mediates the initial 
tethering and rolling of granulocytes, monocytes, and some lymphocytes via specific interac-
tions with its carbohydrate-based ligands. It is then activated by interleukin-1 (IL-1), tumor 
necrosis factor-α (TNF-α), and bacterial LPS—it has to be noted that this may occur only in the 
setting of inflammation [24]. 111In-1.2B6 monoclonal antibody (mAb) is another antibody that 
was used for imaging of selectin activity. Since this is a murine antibody, the administration 
of this radiopharmaceutical comes with a risk of developing human anti-mouse antibody 
(HAMA) response, a possibly life-threatening state that requires immediate medical attention. 
This fact limits the repetition of the study in patients in whom treatment control is necessary. 
Therefore, F(ab’)2 fragments of 1.2B6 mAb—devoid of its Fc portions—were introduced [25].
2.11. Octreotide
Octreotide is a long-acting somatostatin analog that targets the activation of endothelium and 
macrophage recruitment at any of five identified G-protein-coupled somatostatin receptor 
subtypes (SST1–5). Hyper-expression of these receptors has been thoroughly documented in 
numerous pathological conditions hence it can be considered as a basis for octreotide imag-
ing. The synovia of affected joints in RA patients features overexpression of somatostatin 
receptors—those that are targeted by octreotide. The SST2 expression on activated venule of 
endothelial cells and infiltrating mononuclear phagocytes have been identified in histological 
and immunochemistry examinations both in the affected synovia and fibroblast-like synovial 
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cells. It is important to note that patients with favorable treatment results also show signifi-
cantly lower expression of the somatostatin receptors; thus somatostatin scintigraphy may 
also be used in the prediction of the effectiveness of the treatment [26].
Somatostatin receptor expression also features a good correlation with the clinical data—its 
sensitivity estimates 75%. Vanhagen et al. [27] also noted that no radiotracer accumulation 
was observed in the joints of healthy individuals. Numerous works point that somatostatin 
analogs may be used in RA treatment as well. It has also been found that the administration 
of somatostatin analogs reduced the symptoms of the disease—presumably due to the inhibi-
tion of IL-6 and IL-8 production as well as inhibited proliferation that occurs in the affected 
synovium. Therefore, somatostatin scintigraphy may be used as a tool in the prediction of the 
somatostatin analog treatment effects, although until today there has been no randomized 
study to confirm it. Therefore, more research is required before its utility may be introduced 
to the guidelines [28].
2.12. Other radiopharmaceuticals
2.12.1. Anti-CD-3
Since mature T lymphocytes play a role in the development of RA, some radionuclide studies 
make it possible to label monoclonal antibodies against CD3 and T lymphocyte migration into 
the affected synovium. Recent advances allow Muromonab to be labeled with 99mTc and use 
it for imaging of rheumatic disease. It is essential to note that this examination correlates well 
with physical examination and patient history [29]. Moreover, scintigraphy with this tracer 
can be used in differential diagnosis of juvenile idiopathic arthritis and RA as well as other 
rheumatic diseases.
2.12.2. 99mTc-anti-CD4 mAb
Anti-CD4 imaging is also used for the evaluation of T lymphocyte infiltration. CD4 is 
expressed on the cell surface of mature T helper cells, thymocytes, and dendritic cells [30]. 
99mTc-MAX.16H5, murine IgG1 was used in patients and showed affected joints in all RA 
patients. Studies indicate that the sensitivity of the 99mTc-MAX.16H5 scan is better than the 
bone scan.
2.12.3. 99mTc-Anti-CD20 mAb
Almost 95% of circulating normal and malignant B lymphocytes expresses CD20 antigen [31]. 
Furthermore, its expression is exclusive to B lymphocytes simultaneously featuring the lack 
of expression in the hematopoietic stem cells. Due to this fact, Rituximab as a mouse/human 
monoclonal antibody can be labeled with 99mTc and used for B cell infiltration imaging [32].
2.12.4. TNF-alpha
TNF plays an essential role in the development of RA [33]. The promising results have been 
described in studies which involved the use of 123I-anakinra, infliximab (a monoclonal anti-
body that binds to membrane-bound and soluble TNF [34]) and 99mTc-Adalimumab.
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3. Clinical application of radionuclide studies in the setting of 
rheumatoid arthritis and other inflammatory diseases
3.1. Rheumatoid arthritis
3.1.1. Diagnosis and disease progression
In vitro studies of Matsui et al. [35] has shown that in the setting of a murine model of colla-
gen-induced arthritis, the peak of 18F-FDG uptake occurs both at the stage of pannus creation 
and during the destruction of the bone caused by inflammation caused by proliferating fibro-
blasts. Another prominent role of macrophages includes the fact that their inactivated form 
accumulates 18F-FDG merely to a small extent, while glucose demands after their hypoxia-
induced activation increases significantly.
The degree of 18F-FDG uptake in correlation to the disorder severity:
• Moderate uptake can be seen in the initial period of the disease progression, at which inter-
stitial inflammatory cells recruitment, synovial cells hyperplasia, and edema can be seen.
• Uptake of 18F-FDG noticeably increases as the bony destruction and pannus creation 
progresses.
It has been shown that the highest grade of 18F-FDG accumulation not only is related to 
the proliferation of fibroblasts but also to the neutrophils as well. On the other hand, rest-
ing macrophages feature moderate accumulation of 18F-FDG. In the setting of hypoxia, the 
activity of various inflammatory cells changes, while the activity of proinflammatory cyto-
kines (such as TNF-alpha) increases. It has been observed that in these conditions there is 
increased 18F-FDG uptake by macrophages and fibroblasts, while in the case of neutrophils, 
it remains at the background level. T cells accumulate 18F-FDG to a small extent regardless of 
the microenvironment.
Summarizing, the degree of 18F-FDG uptake correlates with the activity of proliferating fibro-
blasts as well as macrophages activated by hypoxia; hence allowing the 18F-FDG study to be 
used in the evaluation of the disease severity.
Beckers et al. [36] assessed that the sensitivity of this technique in the setting of rheumatoid 
arthritis equals approx. 90%. Some works indicate that the study allows the identification of 
lesions in the subclinical phase of the disease as well as at the stage of its clinical remission. 
This fact plays a particularly important role in the treatment [37].
18F-FDG PET-CT study also allows the assessment of the disease severity in other maladies, 
such as spondyloarthritis, polymyalgia rheumatica, Still’s disease, polychondritis, IgG4-
related disease, polymyositis, and dermatomyositis [38].
Some of the studies aimed to assess the usefulness of 11C-choline as a marker for both the diag-
nosis and the severity assessment tool in rheumatic diseases. These indicated that it might be 
a good marker for the proliferation progress, which occur not only in the setting of tumors but 
also in the rheumatic conditions as well.
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Roivainen et al. [39] made a comparison between 11C-choline PET-CT to 18F-FDG and gadolin-
ium-enhanced MRI. The authors have shown that there is very high compliance between the 
pharmacokinetics of 18F-FDG and 11C-choline at the site of the affected joints. Regardless of the 
clinical symptoms of the inflammatory process, the accumulation of both markers occurred 
in the same joints that featured a clear contrast enhancement in the MR study. Moreover, 
authors state that 11C-choline may be a very promising tracer for quantitative imaging of 
proliferative arthritis changes. However, to characterize the relationship of PET-CT results 
with the clinical and functional measures of inflammation, a subsequent prospective study 
involving a larger number of patients is necessary [39]. Among other radiopharmaceuticals, 
11C-(R)-PK11195 isoquinoline carboxamide is also being used for both the diagnosis of RA as 
well as an assessment of the disease severity. It was noted that this tracer tends to accumulate 
primarily in the activated macrophages and its degree of uptake highly corresponds to the 
severity of synovitis priorly assessed by histopathological examination. This examination 
turned out to be highly sensitive in both localizations of acute phase inflammation spots and 
the assessment of initial phase of the disease. It is considered that increased PET signal in 
inflamed joints occurs as a result of specific PBR-mediated uptake of 11C-(R)-PK11195 caused 
by activated macrophages.
Van der Laken et al. [40] performed one of the first studies in the setting of the rheumatic 
disease. The authors concluded in their work that 11C-(R)-PK11195 uptake on the PET scans 
was significantly higher in severely inflamed joints in comparison to those with moderate or 
mild signs of inflammation. Additionally, tracer uptake in contralateral, unaffected by inflam-
mation knee joints of RA patients was significantly higher than in joints of healthy individuals 
from the control group (with no history of inflammatory joint disease or the presence of any 
subclinical disease activity). PET tracer uptake in the affected joints is highly correlated with 
PBR staining of sub-lining of synovial tissue, which also proves its correlation to CD68 stain-
ing of macrophages.
It is believed that this tracer may allow imaging of the ongoing pathology prior to its 
clinical manifestation due to the fact that macrophages infiltration into synovial joints 
is a common feature of asymptomatic synovitis in early RA [41, 42]. Furthermore, the 
application of 11C-(R)-PK11195 imaging to RA may prove to be relevant to patient man-
agement since the presence and the number of macrophages in rheumatoid synovium 
strictly correlates with the progression of joint erosions that can be seen in the X-ray. 
Another use of this trace encompasses diagnosis of subclinical synovitis in patients with 
arthralgia. Last but not least, increased uptake of the tracer correlates with the progres-
sion of the disease.
3.1.2. Treatment control
Numbers of works indicate that 18F-FDG is an excellent marker in the assessment of treatment 
effectiveness. The utility of 18F-FDG as the marker in this assessment was suggested by Palmer 
et al. back in 1995 [43]. The authors in their work studied the influence of prednisolone and 
subsequent methotrexate treatment on findings in MRI and 18F-FDG PET-CT. Results showed 
that as the volume of the pannus seen on MRI decreased, so did the uptake of 18F-FDG—
not to mention the improvement of the clinical picture (such as reduction of pain sensation, 
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stiffness, and edema). However, none of the studied parameters correlated with the outcome 
of the treatment. Authors concluded that both morphological pictures visible in MRI study 
and the functional test of PET study allow the assessment of the quantitative effectiveness of 
the applied therapy.
Similar results were presented in 2004 by Beckers et al. who have shown a direct correlation 
between the clinical picture of a joint with the findings of an ultrasound examination and 
the degree of 18F-FDG uptake in PET-CT [36]. Additionally, as it turned out, the degree of 
18F-FDG uptake in the affected joint highly correlates to the thickness of the synovial mem-
brane priorly assessed in the ultrasound examination. Moreover, another correlation has been 
found between the number of joints with increased 18F-FDG uptake (with consideration of 
their total uptake value) and the duration of the disease together with the degree of sever-
ity. In 2004, Brenner et al. indicated in his work that despite confirmed correlation between 
18F-FDG uptake and the effectiveness of the treatment, PET-CT is still not recommended as 
a routine evaluation tool due to its high costs and limited availability [44]. This technique 
would be more indicated if the findings could provide parameters that are not obtainable by 
other tests (such as MRI, bone scan or ultrasound examination). However, authors pinpoint 
few of such parameters, that is, the possibility of quantitative assessment of disease sever-
ity of each affected joint and the assessment of disease progression as well as monitoring of 
treatment effectiveness. Authors emphasize that further studies are necessary for the better 
determination of PET-CT study indications.
Beckers et al. [36] presented a noteworthy work which aimed to study the response to the anti-
TNF-alpha treatment [44]. Authors in their work showed a significant correlation between the 
degree of 18F-FDG uptake, MRI findings, synovial membrane thickness, and the concentration 
of matrix metalloproteinase (MMP)3 and CRP levels. Similarly, Elzinga et al. [45] showed 
in their work that decreased uptake of 18F-FDG after application of anti-TNF therapy is an 
important prognostic factor that indicates the effectiveness of the treatment.
3.1.3. Prognosis
Elzinga et al. [45] concluded that decreased 18F-FDG uptake in the metacarpophalangeal and 
wrist joints 2 weeks following the infliximab (anti-TNF-alpha) therapy allowed to predict the 
outcome of the treatment after 14 and 22 weeks. It was all possible to achieve that because 
of the presence of clear correlation between the fall of the tracer uptake and the severity of 
the disease, which has subsequently contributed to the development of disease activity score 
(DAS). However, this type of correlation was not found in later observations; thus it requires 
further research. Perhaps another radiopharmaceutical will turn out to be more useful in 
prognosis of anticipated outcomes of the given treatment.
3.2. Diagnosis of concomitant diseases
A PET-CT study is a useful tool in the diagnosis of concomitant neoplastic disorders in 
patients with lupus, systemic sclerosis, dermatomyositis/polymyositis or Sjögren syndrome. 
Epidemiological data in these groups of patients showed the occurrence is noticeably higher; 
especially lymphoma, pharyngeal, and pancreatic cancer [46–48].
Molecular Imaging
http://dx.doi.org/10.5772/intechopen.77200
19
Autoimmune disease treatment involves the use of immunosuppressants, which aim to 
lower the immune response of the organism, simultaneously increasing the risk of infec-
tion (including a higher risk for relapse of tuberculosis) [49]. 18F-FDG PET-CT study turns 
out to the most sensitive test for the diagnosis of infection. This examination can show 
abnormal focal uptake of the tracer in up to 90% of the patients suffering from autoimmune 
diseases; sensitivity and specificity in the diagnosis of neoplastic disorder equal 100 and 
67%, respectively [50].
3.3. Fever of unknown origin
18F-FDG PET-CT also showed to be promising in the diagnostic process in patients with the 
symptoms of FUO. In cases where other imaging studies showed to be inconclusive, 18F-FDG 
PET-CT allows for the localization of pathological foci (either inflammation or a tumor based) 
in approx. 47% of the patients. Positive predictive value of this study has been assessed for 
78% while negative predictive value—for 88% [51].
3.4. Vasculitis
Suspected large vascular vessels vasculitis is another indication for 18F-FDG PET-CT. The term 
of vasculitis emphasizes the numbers of diseases, out of which Takayasu arteritis together 
with giant cell arteritis accounts for the most common types of vasculitis. Sensitivity and 
Figure 2. 18F-FDG PET-CT in patient with RA shows increased accumulation of the tracer in the wall of the aorta.
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specificity of 18F-FDG PET-CT in this setting equal 90%. In a meta-analysis performed by 
Balink et al. [52], the authors point out that sensitivity of this modality is higher than in any 
other imaging method (Figure 2).
4. Conclusion
Indeed, we can say that recently used studies such as MRI, CT or US in the setting of rheu-
matology are the marriage of convenience while radionuclide studies may be considered as a 
marriage of love. Such complex disease processes that occur in rheumatic diseases require com-
prehensive data that can be obtained only by procedures from the field of nuclear medicine.
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